Summary
Background
WHO has identified Marburg virus as an emerging virus requiring urgent vaccine research and development, particularly due to its recent emergence in Ghana. We report results from a first-in-human clinical trial evaluating a replication-deficient recombinant chimpanzee adenovirus type 3 (cAd3)-vectored vaccine encoding a wild-type Marburg virus Angola glycoprotein (cAd3-Marburg) in healthy adults.
Methods
We did a first-in-human, phase 1, open-label, dose-escalation trial of the cAd3-Marburg vaccine at the Walter Reed Army Institute of Research Clinical Trials Center in the USA. Healthy adults aged 18–50 years were assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 or 1 × 1011 particle units (pu). Primary safety endpoints included reactogenicity assessed for the first 7 days and all adverse events assessed for 28 days after vaccination. Secondary immunogenicity endpoints were assessment of binding antibody responses and T-cell responses against the Marburg virus glycoprotein insert, and assessment of neutralising antibody responses against the cAd3 vector 4 weeks after vaccination. This study is registered with ClinicalTrials.gov, NCT03475056.
Findings
Between Oct 9, 2018, and Jan 31, 2019, 40 healthy adults were enrolled and assigned to receive a single intramuscular dose of cAd3-Marburg vaccine at either 1 × 1010 pu (n=20) or 1 × 1011 pu (n=20). The cAd3-Marburg vaccine was safe, well tolerated, and immunogenic. All enrolled participants received cAd3-Marburg vaccine, with 37 (93%) participants completing follow-up visits; two (5%) participants moved from the area and one (3%) was lost to follow-up. No serious adverse events related to vaccination occurred. Mild to moderate reactogenicity was observed after vaccination, with symptoms of injection site pain and tenderness (27 [68%] of 40 participants), malaise (18 [45%] of 40 participants), headache (17 [43%] of 40 participants), and myalgia (14 [35%] of 40 participants) most commonly reported. Glycoprotein-specific antibodies were induced in 38 (95%) of 40 participants 4 weeks after vaccination, with geometric mean titres of 421 [95% CI 209–846] in the 1 × 1010 pu group and 545 [276–1078] in the 1 × 1011 pu group, and remained significantly elevated at 48 weeks compared with baseline titres (39 [95% CI 13–119] in the 1 ×1010 pu group and 27 [95–156] in the 1 ×1011 pu group; both p<0·0001). T-cell responses to the glycoprotein insert and neutralising responses against the cAd3 vector were also increased at 4 weeks after vaccination.
Interpretation
This first-in-human trial of this cAd3-Marburg vaccine showed the agent is safe and immunogenic, with a safety profile similar to previously tested cAd3-vectored filovirus vaccines. 95% of participants produced a glycoprotein-specific antibody response at 4 weeks after a single vaccination, which remained in 70% of participants at 48 weeks. These findings represent a crucial step in the development of a vaccine for emergency deployment against a re-emerging pathogen that has recently expanded its reach to new regions.
Funding
National Institutes of Health.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Access any 5 articles from the Lancet Family of journals
Subscribe:
Subscribe to The Lancet
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 1.
The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts.Antiviral Res. 2018; 159: 63-67
- 2.
Mapping the zoonotic niche of Marburg virus disease in Africa.Trans R Soc Trop Med Hyg. 2015; 109: 366-378
- 3.
Mapping the zoonotic niche of Ebola virus disease in Africa.eLife. 2014; 3e04395
- 4.
Marburg hemorrhagic fever associated with multiple genetic lineages of virus.N Engl J Med. 2006; 355: 909-919
- 5.
Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola.J Virol. 2006; 80: 6497-6516
- 6.
Uganda ends Marburg virus disease outbreak.World Health Organization, Geneva2017
- 7.
First-ever outbreak of Marburg virus disease declared in Ghana, 2022.https://virological.org/t/first-ever-outbreak-of-marburg-virus-disease-declared-in-ghana-2022/897/1Date: 2022Date accessed: December 9, 2022
- 8.
Neglected filoviruses.FEMS Microbiol Rev. 2016; 40: 494-519
- 9.
Ebola and Marburg virus vaccines.Virus Genes. 2017; 53: 501-515
- 10.
Characterization of Marburg virus glycoprotein in viral entry.Virology. 2007; 358: 79-88
- 11.
Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections.Vaccine. 2005; 23: 3033-3042
- 12.
A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates.Sci Transl Med. 2022; 14eabq6364
- 13.
Systematic review of Marburg virus vaccine nonhuman primate studies and human clinical trials.Vaccine. 2021; 39: 202-208
- 14.
Development of a preventive vaccine for Ebola virus infection in primates.Nature. 2000; 408: 605-609
- 15.
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.Nature. 2003; 424: 681-684
- 16.
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.PLoS One. 2018; 13e0192312
- 17.
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.Clin Vaccine Immunol. 2008; 15: 460-467
- 18.
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.Sci Transl Med. 2012; 4115ra2
- 19.
Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization.J Immunol. 2013; 190: 2720-2735
- 20.
Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.Nat Med. 2014; 20: 1126-1129
- 21.
A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines.Vaccine. 2009; 27: 1293-1300
- 22.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.Lancet Infect Dis. 2020; 20: 707-718
- 23.
Chimpanzee adenovirus vector Ebola vaccine.N Engl J Med. 2017; 376: 928-938
- 24.
Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.Lancet Infect Dis. 2016; 16: 311-320
- 25.
A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA.N Engl J Med. 2016; 374: 1635-1646
- 26.
Safety and Immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal.J Infect Dis. 2019; 219: 1187-1197
- 27.
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.Lancet Infect Dis. 2020; 20: 719-730
- 28.
Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia.N Engl J Med. 2017; 377: 1438-1447
- 29.
Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.J Infect Dis. 2015; 211: 549-557
- 30.
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.Sci Transl Med. 2021; 13eabj7211
- 31.
flowAI: automatic and interactive anomaly discerning tools for flow cytometry data.Bioinformatics. 2016; 32: 2473-2480
- 32.
Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.Lancet. 2015; 385: 1545-1554
- 33.
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.Vaccine. 2010; 29: 304-313
- 34.
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.Lancet. 2015; 385: 2272-2279
- 35.
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.Lancet Infect Dis. 2020; 20: 816-826
- 36.
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.Sci Transl Med. 2012; 4115ra1
- 37.
Sabin Vaccine Institute receives additional $34·5 million from BARDA for further development of Ebola Sudan and Marburg vaccines.https://www.sabin.org/resources/sabin-vaccine-institute-receives-additional-34-5-million-from-barda-for-further-development-of-ebola-sudan-and-marburg-vaccines-2/Date: 2021Date accessed: January 9, 2023
Article info
Publication history
Published: 28 January 2023
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Articles
- Developing a vaccine against Marburg virus disease
-
Marburg virus disease is a severe infection in people and non-human primates (NHPs), with a case-fatality rate of 23–90%.1 The disease is caused by the Marburg virus, a member of the Filoviridae family, which includes the viruses responsible for Ebola virus disease.1 Marburg virus disease is extremely rare. Since its discovery in 1967, when two outbreaks occurred simultaneously in laboratories in Marburg and Frankfurt in Germany, and in Belgrade, Yugoslavia (now Serbia), causing 31 cases and seven deaths, there have been 16 known outbreaks with a cumulative total of fewer than 500 reported cases.
- Full-Text
-